缓释注射剂：技术、疗法、市场、预测

Extended-Release Injectable Drugs: Technology, Therapeutics, Markets, & Forecasts

出版日期: 2023年06月12日 | 出版商:

Greystone Research Associates | 英文 200 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

本报告研究了缓释注射药物市场，并提供了市场概况，包括需求趋势、市场促进因素、药物概述以及进入市场的公司概况。

内容

执行摘要
注塑市场动态
倾向于自我管理
注射製剂技术
注射装置设计的创新
治疗需求的驱动因素
市场因素
患者的依从性和可用性
医疗法规
管理式医疗倡议
竞争格局
风险因素
缓释製剂技术
可生物降解聚合物
聚乙二醇
解放军/人民解放军
聚醚酯
缓释製剂平台
BEPO(MedinCell)
ChroniJect (Oakwood Laboratories/PharmaSophia)
CriticalMix (Critical Pharmaceuticals)
Depofoam (Pacira)
FluidCrystal (Camarus)
LinkeRx (Alkermes)
Medisorb (Alkermes)
Medusa (Recipharm/Avadel)
Nanocrystals (Alkermes)
Optisomes (Talon/Spectrum)
PolyActive (Octoplus)
Q-Sphera (Midatech Pharma)
SABER/SAIB (DURECT)
SynBiosys (Innocore)
TransCon (Ascendis)
物理过程控制方法
超临界流体
SCF for Nanoparticle Formulations
Formulplex（超临界溶液）
Ferro
SCF extraction of emulsions (SFEE)
缓释注射剂 - 发育因子
组合元素
稳定
控制因素
缓释注射剂 - 产品分析
阿立□唑
月桂□阿立□唑
布比卡因
丁丙诺啡
阿糖胞甘
阿糖胞甘和柔红霉素
阿霉素
雌二醇
艾塞那□
氟奋乃静癸酸酯
醋酸戈舍瑞林
格拉司琼
干扰素
伊立替康
醋酸兰瑞□
亮丙瑞林
亮丙瑞林长效製剂
甲羟孕酮
纳曲酮
醋酸奥曲□
奥氮平双羟□酸盐
帕潘立酮棕榈酸酯
帕瑞□
Pegvariase-pqpz
利培酮
睪酮
曲普瑞林
曲安奈德
硫酸长春新碱
血糖控制
AB101（Rezolute）
激素缺乏
人类生长激素/Ascendis
成瘾
CAM2038（Camurus）
疼痛管理
Posidur/Durect
心臟病学
曲前列环素/Ascendis Pharma
神经病学
Lerday/Risperidone(DURECT/Zogenix)
肿瘤学
CAM2032（Camurus）
缓释注射剂 - 特定区域分析
成瘾
血糖控制
感染
肝炎
神经病学
精神分裂症
双相情感障碍
肿瘤学
疼痛管理
生殖医学
生育能力
子宫内膜异位症
与更年期相关的血管舒缩症状
公司简介
Alkermes
Amylin
AntriaBio
Ascendis Pharma
AstraZeneca
Aurobundo
Avadel
Biomarin
Camurus
Critical Pharmaceuticals
DURECT
Eli Lilly
Enzon
Ipsen
Janssen
NanOlogy
Novartis
OctoPlus
Oakwood Laboratories/PharmaSophia
Pacira
PhaseBio Pharmaceuticals
Recipharm AB
Roche
Sanofi
Taiwan Liposome Company (TLC)
Xbrane Bipharma

简介目录

This new market study, “Extended-Release Injectable Drugs: Technology, Therapeutics, Markets and Forecasts ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drug products engineered for controlled release. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to produce APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

What You Will Learn:

What are the marketed Extended-Release injectable drug products, what Extended-Release formulation technologies are used, and who markets them?

What are the major factors driving Extended-Release injectable drug demand?

What Extended-Release injectable drug candidates are in late-stage clinical development and what is their potential impact?

How important are drug developer-formulation technologist relationships in the Extended-Release market segment, and what are the key alliances in the industry?

What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for Extended-Release injectable drug products?